Nuvalent, Inc.
NUVL
Rankning i aktier
#2113
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Aktiekurs
$123.96
Senast synkroniserad: 2026-07-21
Marknadsvärde
$9.75B
Förändring (1 dag)
0.00%
Förändring (1 år)
27.56%
Land
US
Handel Nuvalent, Inc. (NUVL)
Kategori
Healthcare
Antal utestående aktier för Nuvalent, Inc. (NUVL)
Antal utestående aktier per March 2026: 78.67M
Enligt de senaste finansiella rapporterna och aktiekursen för Nuvalent, Inc. är det aktuella antalet utestående aktier 78.67M. I slutet av December 2023 hade företaget 58.22M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Nuvalent, Inc. (NUVL) från 2019 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 78.67M | 18.46% |
| 2024 | 66.41M | 14.06% |
| 2023 | 58.22M | 17.22% |
| 2022 | 49.67M | 128.02% |
| 2021 | 21.78M | -4.73% |
| 2020 | 22.86M | -52.65% |
| 2019 | 48.28M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 222.74% |
US
|
|
| 396.00M | 403.37% |
US
|
|
| 478.91M | 508.76% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -20.95% |
NL
|
